{"itemsPerPage":10,"pageSum":null,"page":1,"items":1,"htmlContent":"
\n
\n Enliven Therapeutics报告第一季度财务业绩并提供业务更新\n

(MENAFN - PR Newswire)\nUpdated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June\nEHA abstract reported cumulative MMR rate of 44% (16 of ...

\n
\n
\n \n menafn\n \n 2025-06-06\n
\n
\n
\n
\n"}